Skip to main content

Drug Safety

Thromboembolic Risk with Tofacitinib in RA, PsA and UC

Aug 06, 2020

An analysis of the tofacitinib (Xeljanz) drug development program in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ulcerative colitis suggests a low level risk for venous (VTE) and arterial thromboembolism (ATE).  



In the last 2 years, observational data has

Read Article

Long-Term Rituximab in ANCA-Associated Vasculitis

Aug 06, 2020

The Annals of Internal Medicine reports that biannual rituximab infusions over 18 months was effective at maintaining remission in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV).

Read Article

Methotrexate Not Associated with Interstitial Lung Disease

Aug 05, 2020

A case-controlled study shows that methotrexate (MTX) use in rheumatoid arthritis (RA) is not associated with interstitial lung disease (ILD) according to a report in the European Respiratory Journal.



Researchers examined the associatioin by comparing 410 RA patients with

Read Article

IL-1 Blockade: A Treatment at Last for Osteoarthritis?

Aug 05, 2020

The interleukin (IL)-1β inhibitor canakinumab (Ilaris) showed promise for preventing the need for hip or knee replacement among patients with osteoarthritis in an exploratory analysis of data from a randomized clinical trial, investigators reported.

Among patients enrolled in CANTOS, the pooled

Read Article

Lovastatin Fails to Lower CRP and Activity in RA

Aug 04, 2020

Ridker and colleagues have shown that statins (3-hydroxy-3-methylglutaryl coenzyme-A (HMG Co-A) reductase inhibitors) are effective at treating hyperlipidaemia and lowering C-reactive protein levels; Aranaow and colleagues have shown that lovastatin, when given to rheumatoid arthritis (RA)

Read Article

Fighting Hydroxychloroquine Misinformation

Aug 03, 2020

JAMA Internal Medicine has posted an Editor's note on the use of hydroxychloroquine for COVID-19; noting the sequence of dysfunction since the president promoted its use on March 21, 2020, when he said “What do you have to lose? I’ll say it again: What do you have to lose? Take it

Read Article

More Rheumatology Fellow Advice from the Mentors

Aug 03, 2020

If you’re looking for some great advice to consider or rebuke, here is the generous guidance of nearly two dozen leaders in rheumatology who sincerely offer you their wisdom and best wishes.

Read Article

Uric Acid Targeting in Gout Management

Jul 31, 2020

A study from 2 gout clinics implementing different treatment strategies has shown that a treatment strategy that aims to strictly achieve low uric acid (UA) results in a higher a rate of targetd serum UA lowering and less gout flares.



Two gout clinics with 212 newly diagnosed gout

Read Article

Methotrexate Improves Pegloticase Efficacy and Tolerability

Jul 29, 2020

The efficacy of intravenous pegloticase (PEG) therapy in gout can be limited by its toxicity, but when coadministered with weekly methotrexate, higher response rates and less toxicity was observed.



In published gout clinical trials, the PEG responder rate was 42%. Strategies to limit 

Read Article

The Burden of Gout

Jul 28, 2020

Danve and Neogi have an editorial in the current Arthritis & Rheumatology about the burden of gout that affects 41 million adults worldwide, according to the Global Burden of Disease Study 2017 (GBD 2017) also published in the same issue.

This makes gout twice as prevalent as rheumatoid

Read Article

SEMIRA Study: Best to Continue Low Dose Steroids in RA

Jul 28, 2020

The SEMIRA trial studied the  tapering vs continuing oral glucocorticoids in rheumatoid arthritis (RA) patients who achieved a low disease activity state (with tocilizumab) were more likely to show safety and better disease control with continuing steroids - even though two-thirds of patients

Read Article

RheumNow Podcast – COVID-19 Responds to Steroids (7.24.20)

Jul 24, 2020

Dr. Jack Cush reviews the News and Journal Reports from the past week on RheumNow.com.

Read Article

Low Risk of COVID in Biologic Treated Rheum Patients

Jul 23, 2020

In an Annals of Rheumatic Disease report, Italian investigators performed consecutive testing for SARS-CoV-2 (IgM and IgG) between 25 March to 25 May 2020 and compared test results between rheumatic disease (RMD) patients and the general population. 



Their study included 295

Read Article

For TNF Response in RA, Weight Matters

Jul 22, 2020

Patients with rheumatoid arthritis (RA) who were obese were significantly less likely to remain on treatment with tumor necrosis factor (TNF) inhibitors -- but so were those who were underweight, a large, long-term study determined.

Compared with patients with normal weight, patients in obesity

Read Article

Risankizumab Outduels Secukinumab in Psoriasis

Jul 20, 2020

The IMMerge trial has demonstrated the superiority of interleukin (IL)‐23 over IL-17A inhibition adults with plaque psoriasis.



This multicenter, phase 3, open‐label study enrolled 327 adult patients with chronic, moderate‐to‐severe plaque psoriasis who were randomised risankizumab (

Read Article

RECOVERY Trial: Dexamethasone in COVID-19

Jul 20, 2020

Inflammatory events following infection with SARS-CoV-2 can often worsen the morbid or mortal outcomes with COVID, yet it has been unclear if glucocorticoids may modulate inflammation-mediated damage and lung injury.  The RECOVERY trial reports that dexamethasone (DEX) use lowered 28-day

Read Article
Single center retrospective Korean study of 1280 Ankylosing Spondylitis patients (595 exposed to TNFi) showed that TNFi was associated with significantly decreased Xray change rate (mSASSS) (β=−0.112, p=0.004). https://t.co/W4j0Ckt0R2

Dr. John Cush RheumNow ( View Tweet)

Jul 20, 2020

Meloxicam Superior to Placebo and Cognitive Behavioral Therapy in Knee OA

Jul 20, 2020

Pain management in knee osteoarthritis (OA) is confounded by studies showing less is equal to usual standards of care. A recent trial showed that meloxicam was superior to placebo or cognitive behavioral therap (CBT); although the differences were small. 

Read Article
Bisphosphonate therapy may be protective against radiographic knee OA progression in early‐stage patients (KL grade < 2) (HR 0.53), especially non-obese. Study from 1977 women in the Osteoarthritis Initiative. https://t.co/tZhovfMWTh

Dr. John Cush RheumNow ( View Tweet)

Jul 20, 2020
A randomized controlled trial testing dexamethasone for Covid-19 (the RECOVERY trial) showed that, compared with usual care, this corticosteroid drug reduced 28-day mortality in hospitalized patients. #COVID19 #SARSCoV2

NEJM NEJM ( View Tweet)

Jul 19, 2020
MMWR reports 2019 survey data showing 6.6% of women used opioid during pregnancy. 21% admitted misuse, 27% wanted to stop/reduce narcotic use and 32% did not receive MD counseling about how opioid use could affect an infant. https://t.co/Ybrjv4Anmk

Dr. John Cush RheumNow ( View Tweet)

Jul 17, 2020
Regeneron/Sanofi have reported their US phase 3 trial of Kevzara (sarilumab) 400 mg given to 194 critically ill COVID-19 patients, requiring mechanical ventilation, did not meet its primary and key secondary endpoints when added to supportive care.

Dr. John Cush RheumNow ( View Tweet)

Jul 17, 2020

HCQ May Help Prevent Fetal Heart Block

Jul 16, 2020

Hydroxychloroquine (HCQ) helped reduce recurrent maternal autoantibody-mediated congenital heart block (CHB) in fetuses, an open-label study suggested.



Anti-SSA/Ro-positive mothers who had had a previous pregnancy complicated by CHB who took HCQ 400 mg daily, starting before

Read Article
The preliminary #ACR20 schedule is here! Along with all your favorite plenary and networking sessions, the program will feature #Rheumatologist Dr. Anthony Fauci giving us a live update on #COVID19.

Victoria Shanmugam VickiShanmugam ( View Tweet)

Jul 16, 2020
NY Times Ranks COVID Rx Tracker: 1) Strong Evidence - Remdesivir, dexamethasone, Ventilation, Proning, anticoagulants; 2) Promising: convalescent plasma, Cytosorb, dialysis; 3) Mixed: IFN, Cytokine inhibitors, Stem Cells; 4) HCQ -not promising https://t.co/sbotsdYcg

Dr. John Cush RheumNow ( View Tweet)

Jul 16, 2020
×